Comparison of human platelet lysate and 10% fetal bovine serum on mesenchymal stem cell viability, proliferation, migration and paracrine factor expression
##plugins.themes.bootstrap3.article.main##
Putri Diana Roza
https://orcid.org/0009-0006-2744-8579
Maisarah Effajri Putri
https://orcid.org/0009-0003-8978-1842
Amaliyah Rifdah Zulwa
https://orcid.org/0009-0007-2247-4804
Afifah Marwa Marbun
https://orcid.org/0009-0004-7134-8036
Ulfah Ulfah
https://orcid.org/0000-0001-9462-9325
Nicko Pisceski Kusika Saputra
https://orcid.org/0000-0003-4431-4565
Rahmat Azhari Kemal
https://orcid.org/0000-0002-1630-9526
Arfianti Arfianti
https://orcid.org/0000-0003-3331-5044
Abstract
Human platelet lysate (HPL) has been proposed as an alternative source to foetal bovine serum (FBS) for culturing mesenchymal stem cells (MSCs), as it eliminates the risk of xenogenicity and may facilitate clinical application. The purpose of this study was to compare the effects of HPL and FBS on MSC viability, proliferation, migration, and expression of paracrine factors. MSCs were cultured in media supplemented with 10% FBS (control), 5% HPL and 10% HPL. Cell viability was determined by the trypan blue dye exclusion and proliferation was assessed using the Cell Counting Kit-8 (CCK-8) assay. MSC migration was evaluated by wound scratch assay after 24 and 48 h of incubation. The expression of the IL-6, VEGF, and TGF-β, which are paracrine factors, was quantified by quantitative real-time polymerase chain reaction (qRT-PCR). The results showed that there was no statistically significant differences in viability, proliferation, and migration were observed between MSCs treated with 5% and 10% HPL and the control group (10% FBS) for 24 and 48. Expression of IL-6, VEGF, and TGF-β was also similar between MSCs cultured in 5% HPL and those cultured in 10% FBS, indicating equivalent functional properties of the cells under both conditions. HPL at 5% supported MSC growth and paracrine factor expression comparably to 10% FBS in vitro. Therefore, 5% HPL may serve as an effective, xeno-free substitute for 10% FBS in MSC culture for clinical applications.
Downloads
##plugins.themes.bootstrap3.article.details##
Copyright (c) 2026 Putri Diana Roza, Maisarah Effajri Putri , Amaliyah Rifdah Zulwa, Afifah Marwa Marbun, Ulfah Ulfah, Nicko Pisceski Kusika Saputra, Rahmat Azhari Kemal, Arfianti Arfianti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
1. Roza PD, Maryanti Y, Ulfah U, Saputra NPK, Arfianti A. Therapeutic potentials of mesenchymal stem cells for cognitive impairment in stroke: Evidence from preclinical studies. Biomed Res Ther. 2024;11(12):7015–7023. https://doi.org/ 10.15419/bmrat.v11i12.947
2. Hassan MNFB, Yazid MD, Yunus MHM, Chowdhury SR, Lokanathan Y, Idrus RBH, Ng AMH, Law JX. Large-scale expansion of human mesenchymal stem cells. Stem Cells Int. 2020;2020:9529465. https://doi.org/10.1155/2020/9529465.
3. Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?. Stem Cells Transl Med. 2020;9(1):17-27. https://doi.org/10.1002/sctm.19-0202
4. Mei R, Wan Z, Yang C, Shen X, Wang R, Zhang H, Yang R, Li J, Song Y, Su H. Advances and clinical challenges of mesenchymal stem cell therapy. Front Immunol. 2024;15:1421854. https://doi.org/10.3389/fimmu.2024.1421854
5. Weber T, Malakpour-Permlid A, Chary A, D'Alessandro V, Haut L, Seufert S, Wenzel EV, Hickman J, Bieback K, Wiest J, Dirks WG, Coecke S, Oredsson S. Fetal bovine serum: how to leave it behind in the pursuit of more reliable science. Front in Toxicol. 2025;7:1612903. https://doi.org/10.3389/ftox.2025.1612903
6. Silva Couto P, Stibbs DJ, Springuel P, Schultz U, Effenberger M, Goldrick S, Navarro-Velázquez S, Juan M, Herbst L, Nießing B, Mestermann K, Sanges C, Hudecek M, Rafiq QA. Impact of serum/xeno‐free medium and cytokine supplementation on CAR‐T cell therapy manufacturing in stirred tank bioreactors. Biotechnol J. 2025;20(9):e70114. https://doi.org/10.1002/biot.70114
7. Strecanska M, Sekelova T, Smolinska V, Kuniakova M, Nicodemou A. Automated manufacturing processes and platforms for large-scale production of clinical-grade mesenchymal stem/ stromal cells. Stem Cell Rev Rep. 2025;21(2):372–389. https://doi.org/10.1007/s12015-024-10812-5
8. Oeller M, Laner‐plamberger S, Krisch L, Rohde E, Strunk D, Schallmoser K. Human platelet lysate for good manufacturing practice-compliant cell production. Int J Mol Sci. 2021;22(10):5178. https://doi.org/10.3390/ijms22105178
9. Rosmarwati E, Ellistasari EY, Kusumawardani A, Julianto I, Widhiati S, Setyawan NA, Yanuar F. Human platelet lysate-derived exosomes are superior to the lysate at increasing collagen deposition in a rat model of intrinsic aging. J Appl Pharm Sci. 2023;13(6):211–216. https://doi.org/10.7324/JAPS.2023.125707
10. Palombella S, Perucca Orfei C, Castellini G, Gianola S, Lopa S, Mastrogiacomo M, Moretti M, de Girolamo L. Systematic review and meta-analysis on the use of human platelet lysate for mesenchymal stem cell cultures: comparison with fetal bovine serum and considerations on the production protocol. Stem Cell Res Ther. 2022;13(1):142. https://doi.org/10.1186/s13287-022-02815-1
11. Olmedo-Moreno L, Aguilera Y, Baliña-Sánchez C, Martín-Montalvo A, Capilla-González V. Heterogeneity of in vitro expanded mesenchymal stromal cells and strategies to improve their therapeutic actions. Pharmaceutics. 2022;14(5):1112. https://doi.org/10.3390/pharmaceutics14051112
12. Lim YT, Barathan M, Tan YL, Lee YT, Law JX. Calcium chloride vs. mechanical preparation of fibrinogen-depleted human platelet lysate: Implications for umbilical cord mesenchymal stem cell culture. Life. 2025;15(1):12. https://doi.org/10.3390/life15010012
13. Cañas-Arboleda M, Beltrán K, Medina C, Camacho B, Salguero G. Human platelet lysate supports efficient expansion and stability of wharton’s jelly mesenchymal stromal cells via active uptake and release of soluble regenerative factors. Int J Mol Sci. 2020;21(17):6284. https://doi.org/10.3390/ijms21176284
14. Liao G, Liao Y, Li D, Fu Z, Wu S, Cheng D, Ouyang Q, Tang Z, Zeng G, Liang X, Xu S, Hu J, Liu M. Human platelet lysate maintains stemness of umbilical cord-derived mesenchymal stromal cells and promote lung repair in rat bronchopulmonary dysplasia. Front Cell Dev Biol. 2021;9:722953. https://doi.org/10.3389/fcell.2021.722953
15. Lei T, Liu Y, Deng S, Xiao Z, Yang Y, Zhang X, Bi W, Du H. Hydrogel supplemented with human platelet lysate enhances multi-lineage differentiation of mesenchymal stem cells. J Nanobiotechnology. 2022;20(1):176. https://doi.org/10.1186/s12951-022-01387-9
16. Du P, Tao X, Harati J, Shi Y, Xiao L, Li X, Pan H, Wang PY. Human platelet lysate enhances small lipid droplet accumulation of human MSCs through MAPK phosphorylation. Stem Cell Res Ther. 2024;15(1):473. https://doi.org/10.1186/s13287-024-04085-5
17. Bzinkowska A, Sarnowska A. Assessment of the dose-dependent effect of human platelet lysate on wharton’s jelly-derived mesenchymal stem/stromal cells culture for manufacturing protocols. Stem Cells Cloning. 2024;17:21–32. https://doi.org/10.2147/SCCAA.S471118
18. Kirsch M, Rach J, Handke W, Seltsam A, Pepelanova I, Strauß S, Vogt P, Scheper T, Lavrentieva A. Comparative analysis of mesenchymal stem cell cultivation in fetal calf serum, human serum, and platelet lysate in 2D and 3D systems. Front Bioeng Biotechnol. 2021;8:598389. https://doi.org/10.3389/fbioe.2020.598389
19. Pilbauerova N, Schmidt J, Suchankova Kleplova T, Soukup T, Suchanek J. Effect of human platelet lysate as cultivation nutrient supplement on human natal dental pulp stem cell in vitro expansion. Biomolecules. 2022;12(8):1091. https://doi.org/10.3390/biom12081091
20. Bian D, Wu Y, Song G, Azizi R, Zamani A. The application of mesenchymal stromal cells (MSCs) and their derivative exosome in skin wound healing: A comprehensive review. Stem Cell Res Ther. 2022;13(1):24. https://doi.org/10.1186/s13287-021-02697-9
21. Han Y, Yang J, Fang J, Zhou Y, Candi E, Wang J, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther. 2022;7(1):92. https://doi.org/10.1038/s41392-022-00932-0
22. Wei E, Hu M, Wu L, Pan X, Zhu Q, Liu H, et al. TGF-β signaling regulates differentiation of MSCs in bone metabolism: disputes among viewpoints. Stem Cell Res Ther. 2024;15(1):156. https://doi.org/10.1186/s13287-024-03761-w